U.S. FDA investigating AstraZeneca's COVID-19 vaccine candidate
Reuters
Published Sep 15, 2020 03:03PM ET
(Reuters) - The U.S. Food and Drug Administration said on Tuesday AstraZeneca (NYSE:AZN) Plc's COVID-19 vaccine trial in the United States is still on hold, and it was working with the company to figure out if there was a significant safety issue or not.
"We don't have all facts, so we don't know the causation per se of this, but we really need to look into it. And our prime responsibility is the safety of the American people," Commissioner Stephen Hahn said in an Instagram live session with Senator Tim Scott.
Reuters had on Monday reported based on sources the U.S. trial was still on hold, pending FDA and safety panel investigations.
Enrollment in the British drugmaker's global trials of the vaccine, which it is developing with researchers at Oxford University, was paused on Sept. 6, after a safety event was reported in its UK trial.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.